Pathology consultation on drug-induced hemolytic anemia

N/ACitations
Citations of this article
66Readers
Mendeley users who have this article in their library.

Abstract

Drug-induced immune hemolytic anemia is considered to be rare but is likely underrecognized. The consulting pathologist plays a critical role in integrating serologic findings with the clinical history, as drug-induced antibodies should be distinguished as either drug-dependent or drug-independent for appropriate clinical management. Drug-dependent antibodies (DDABs) are most commonly associated with cefotetan, ceftriaxone, and piperacillin, whereas fludarabine, methyldopa, β-lactamase inhibitors, and platinum-based chemotherapeutics are frequent causes of drug-independent antibodies (DIABs). DDABs usually demonstrate a positive direct antiglobulin test and a negative elution, while DIABs are serologically indistinguishable from warm autoantibodies and are similarly steroid-responsive. Drug cessation is always recommended. © American Society for Clinical Pathology.

Cite

CITATION STYLE

APA

Pierce, A., & Nester, T. (2011). Pathology consultation on drug-induced hemolytic anemia. American Journal of Clinical Pathology, 136(1), 7–12. https://doi.org/10.1309/AJCPBVLJZH6W6RQM

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free